ADVERTISEMENT

Home|Journals|Articles by Year|Audio Abstracts
 

Case Report

SAJEM. 2021; 4(2): 41-43


Always Read The Fine Print - Cyanide Toxicity From Ingestion Of Vitamin B17 Tablets: A Case Report

Mohammad Anzal Rehman, Mohamed Moheb El Abd, Laila Hussein, Lara S.M. Abumuaileq.



Abstract
Download PDF Cited by 0 ArticlesPost

The use of vitamins and minerals as supplements is highly prevalent in most patient populations, owing to their purported long-term benefits and relative lack of harm on continued use. However, similarly marketed supplements may contain ingredients that can harm the user. Our case highlights a 45-year-old male who ingested several tablets of a supplement known as vitamin B17, Amygdalin, with subsequent fatigue, mild lactic acidosis, and worsening shortness of breath. He was treated as a case of cyanide toxicity based on clinical suspicion and improved subsequently.
The case describes the potential harm from unregulated substances, particularly those purchased online. Vitamin B17, or Amygdalin, may be present in various anti-cancer supplementation and caution is advised in its use due to its association with cyanide poisoning.

Key words: Amygdalin, Cyanide Toxicity, Vitamin B17, Case Report







Bibliomed Article Statistics

54
32
66
68
59
72
79
86
78
42
31
12
R
E
A
D
S

104

107

80

48

74

139

130

178

255

135

168

41
D
O
W
N
L
O
A
D
S
070809101112010203040506
20252026

Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Author Tools
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.